SEATTLE, WASHINGTON--(Marketwire - June 02, 2010) - VentriPoint Diagnostics Ltd. (TSX VENTURE: VPT) of Seattle, WA, has completed the installation of a commercial version of the VentriPoint Medical System (VMS) for use in a clinical study at the echocardiography lab in the Labatt Family Heart Centre at The Hospital for Sick Children (SickKids) in Toronto.The study will test the accuracy of the VMS system to monitor right ventricular function in patients with the congenital heart condition Tetralogy of Fallot.
"As one of Canada's most research-intensive hospitals and one of the leading centers in the world for the care of children with congenital heart disease, SickKids is an ideal hospital setting for the first commercial installation of a VentriPoint Medical System," said Joseph Ashley, VentriPoint's CEO. "The Company is encouraged that the use of the VMS will be rapidly integrated into the routine care of patients with heart disease. We expect many more installations to follow, given the tremendous interest in VMS from medical institutions in Canada, the United States and Europe."
VentriPoint also announces that it filed its unaudited consolidated quarterly financial statements and related management's discussion and analysis ("MD&A") for the three months ended March 31, 2010. These filings are available in their entirety at www.sedar.com.
The VentriPoint Medical System (VMS) generates critical heart measurements with greater speed and accuracy and less expense than is currently possible, and it generates those measurements from the two-dimensional ultrasound systems that are used widely in hospitals and clinics throughout the world. Health Canada and Europe have granted license approval for this breakthrough diagnostic tool, and VentriPoint is in the final stages of the 501(k) review by the U.S. Federal Drug Administration.
VentriPoint Diagnostics Ltd. creates diagnostic tools to monitor patients with heart disease, the number one cause of death in developed countries. The VMS, along with its associated online service, is being adapted for a variety of heart-related diseases, initially for congenital heart disease with pulmonary hypertension to shortly follow.